

April 7, 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs,

Re: Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

We refer to the prospectus of the Company dated April 7, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualifications and opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being made available for display as described in the section headed “Documents Delivered to the Registrar of Companies and Available on Display – Documents Available on Display” in Appendix V to the Prospectus. We also consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus.

Yours faithfully,

[The remainder of this page is intentionally left blank]

Morgan Stanley Asia Limited

A handwritten signature in black ink, appearing to read 'Alvin Cheung', written over a horizontal line.

Name: Alvin Cheung

Title: Executive Director

April 7, 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs,

Re: Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

We refer to the prospectus of the Company dated April 7, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.


We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualifications and opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being made available for display as described in the section headed “Documents Delivered to the Registrar of Companies and Available on Display – Documents Available on Display” in Appendix V to the Prospectus. We also consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus.

Yours faithfully,

[The remainder of this page is intentionally left blank]

Jefferies Hong Kong Limited

A handwritten signature in black ink, appearing to read 'Ryan Chung', is written over a horizontal line. The signature is stylized with a long, sweeping flourish extending to the right.

Name: Ryan Chung
Title: Senior Vice President

April 7 , 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs,

Re: Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

We refer to the prospectus of the Company dated April 7 , 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualifications and opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being made available for display as described in the section headed “Documents Delivered to the Registrar of Companies and Available on Display – Documents Available on Display” in Appendix V to the Prospectus. We also consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of the registration of the Prospectus.

Yours faithfully,

[The remainder of this page is intentionally left blank]

**FOR AND ON BEHALF OF:
CITIC SECURITIES (HONG KONG) LIMITED**

By:

A handwritten signature in black ink, appearing to be 'Ryan Zhao', written over a horizontal line.

Name: Ryan Zhao

Title: Executive Director

CM Law Firm
2805, Plaza 66 Tower 2
1366 West Nanjing Road
Shanghai
PRC

April 7, 2025

The Board of Directors

Duality Biotherapeutics, Inc. 映恩生物

4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs/Madams,

Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We refer to the prospectus of the Company dated April 7, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the ordinary shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus by the Company, with the inclusion therein of all references to our names, address, qualifications, confirmations and opinions in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange and referring to it in the Prospectus.

We also consent to a copy of our PRC legal opinions and this letter being made available on display as described in the section headed “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix V to the Prospectus.

-signature page to follow-

Yours faithfully,
For and on behalf of

CM Law Firm



April 7, 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs/Madams,

Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We refer to the prospectus of the Company dated April 7, 2025 (the “Prospectus”) in connection with the proposed global offering and listing of the ordinary shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications and opinions and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our opinion referred to above being made available on display as described in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix V to the Prospectus.

[The remainder of this page is intentionally left blank]

(Signature Page of Project Diamond - Expert Consent Letter)

Yours faithfully,
For and on behalf of
JunHe LLP



JunHe LLP

April 7, 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs/Madams,

Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We refer to the prospectus of the Company dated April 7, 2025 (the “Prospectus”) in connection with the proposed global offering and listing of the ordinary shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications and opinions and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our opinion referred to above being made available on display as described in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix V to the Prospectus.

[The remainder of this page is intentionally left blank]

(Signature Page of Project Diamond - Expert Consent Letter)

Yours faithfully,
For and on behalf of
Jun He Law Offices P.C.

Jun He Law Offices P.C.
Jun He Law Offices P.C.

Date: April 7, 2025

062011.0002

The Board of Directors

Duality Biotherapeutics, Inc. 映恩生物

4th Floor, Harbour Place

103 South Church Street

George Town

P.O. Box 10240

Grand Cayman KY1-1002

Cayman Islands

Dear Sirs/Madams,

Duality Biotherapeutics, Inc. 映恩生物 (the Company)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the Stock Exchange)

We refer to the prospectus of the Company dated April 7, 2025 (the **Prospectus**) in connection with the proposed global offering and listing of the ordinary shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications and opinions and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and the letter of advice referred to above being made available on display as described in "Documents Delivered to the Registrar of Companies and Available on Display" in Appendix V to the Prospectus.

[signature page to follow]

Yours faithfully

Harney Westwood & Riegels

Harney Westwood & Riegels



羅兵咸永道

The Board of Directors
Duality Biotherapeutics, Inc.
4th Floor, Harbour Place, 103 South Church
Street, George Town, P.O. Box 10240, Grand
Cayman KY1-1002, Cayman Islands

7 April 2025

Dear Sirs,

We refer to the prospectus dated 7 April 2025 in connection with the proposed initial listing of shares of Duality Biotherapeutics, Inc. (the "Company") on the Main Board of The Stock Exchange of Hong Kong Limited (the "Prospectus"), a copy of which is attached and initialled by us on its front cover for the purpose of identification.

Our engagement to prepare this letter has been performed in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 200, *Accountants' Reports on Historical Financial Information in Investment Circulars* issued by the Hong Kong Institute of Certified Public Accountants.

We hereby consent to the inclusion of our accountant's report and our report on unaudited pro forma financial information, both dated 7 April 2025, in the Prospectus, and the references to our name in the form and context in which they are included.

Yours faithfully,

A handwritten signature in blue ink that reads "PricewaterhouseCoopers".

PricewaterhouseCoopers
Certified Public Accountants
Hong Kong

April 7, 2025

The Board of Directors
Duality Biotherapeutics, Inc. 映恩生物
4th Floor, Harbour Place
103 South Church Street
George Town
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Dear Sirs/Madams,

Duality Biotherapeutics, Inc. 映恩生物 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)


We refer to the prospectus of the Company dated April 7, 2025 (the “Prospectus”) in connection with the proposed global offering and listing of the ordinary shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications, opinions, report and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our report referred to above being made available on display as described in the section headed “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix V to the Prospectus.

[The remainder of this page is intentionally left blank]

Yours faithfully,
For and on behalf of
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Charles Lau
Title: Executive Director